Category
Cancer
Sub Category
Myeloma
Study Name
i071-341-03 VELCADE: Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV VELCADE (Bortezomib) with Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma Following at Least One Prior Therapy
Principal Investigator
Gordan Srkalovic MD, PhD
Study Information
Patients must have refractory/relapsed MM and progression of disease
Contact for Questions
Sparrow Cancer Center 800-968-5570

Site view: at a glance